Berner M, Hartmann A, Erber R (2023)
Publication Type: Journal article
Publication year: 2023
Book Volume: 30
Pages Range: 195-202
Journal Issue: 3
DOI: 10.1097/PAP.0000000000000382
Immune checkpoint inhibitors (ICIs) have changed therapy strategies in breast cancer (BC) patients suffering from triple-negative breast cancer (TNBC). For example, in Europe the anti-programmed cell death 1 ligand 1 (PD-L1) ICI Azetolizumab is approved for adult patients with locally advanced or metastasized TNBC (mTNBC), depending on the immunohistochemical (IHC) PD-L1 expression of immune cells in the tumor area [immune cell (IC) score ≥1%); the anti-programmed cell death 1 (PD-1) ICI pembrolizumab is approved for mTNBC if PD-L1 Combined Positive Score (CPS), that is PD-L1 expression on tumor and/or immune cells, is ≥10. For early TNBC, in contrast, neoadjuvant use of pembrolizumab is approved in the United States and Europe independent from PD-L1 IHC expression. The determination of PD-L1 expression in tumor tissue to predict response to ICI therapy requires sensitive immunostaining with appropriate primary antibodies and staining protocols and a standardized and meticulous assessment of PD-L1 IHC stained breast cancer tissue slides. For the selection of the test material and continuous quality control of the dyeing, high standards must be applied. The evaluation is carried out according to various evaluation algorithms (scores). Here, the role of PD-L1 in BC and the currently most relevant PD-L1 assays and scores for TNBC will be explained. Furthermore, other tissue-based biomarkers potentially predictive for ICI therapy response in BC, for example, tumor mutational burden (TMB), will be presented in this review.
APA:
Berner, M., Hartmann, A., & Erber, R. (2023). Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer. Advances in Anatomic Pathology, 30(3), 195-202. https://doi.org/10.1097/PAP.0000000000000382
MLA:
Berner, Mandy, Arndt Hartmann, and Ramona Erber. "Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer." Advances in Anatomic Pathology 30.3 (2023): 195-202.
BibTeX: Download